Study Links Psychiatric Medications to Increased ALS Risk

Recent research from the Karolinska Institute in Sweden has unveiled a concerning association between commonly prescribed psychiatric medications and an increased risk of developing amyotrophic lateral sclerosis (ALS), the most prevalent form of motor neurone disease (MND). This study, published in JAMA Network Open in June 2025, highlights the potential implications of psychiatric treatments on neurological health.
The research examined health data from Sweden, comparing 1,057 ALS patients diagnosed between 2015 and 2023 with over 5,000 matched controls who had no MND diagnosis. According to the findings, the use of anxiolytics, hypnotics, and antidepressants was linked to a 34%, 21%, and 26% increased risk of developing ALS, respectively. While these figures may seem alarming, the researchers noted that the overall prevalence of ALS remains low, thus placing the increased risk in a broader context.
Dr. Anna Chourpiliadis, the lead author of the study, emphasized the importance of understanding these associations. "In this case-control study, prescribed use of anxiolytics, hypnotics, or antidepressants was associated with a higher subsequent risk of ALS," she stated. Furthermore, the study indicated that prediagnostic use of these medications correlated with a poorer prognosis following an ALS diagnosis, including an accelerated rate of decline and a heightened risk of mortality among those affected.
Despite these findings, the researchers urged caution in interpreting the results. The possibility that other health-related factors, such as the underlying psychiatric conditions themselves, could contribute to both the prescription of these medications and the likelihood of an ALS diagnosis cannot be disregarded. Dr. Susannah Tye, a neuroscientist at the University of Queensland and not involved in the study, remarked, "This study adds to growing evidence that individuals with psychiatric conditions may face an elevated risk of neurodegenerative diseases such as ALS. However, the implication that psychiatric medications themselves contribute to this risk should be interpreted with caution."
The implications of this research are significant, especially considering the rising prescription rates of psychiatric medications in recent years. Depression and anxiety are prevalent conditions, with millions of individuals relying on these treatments without developing ALS. The focus of ongoing research should now shift toward understanding the interplay between psychiatric disorders and neurodegenerative diseases, potentially paving the way for better treatment strategies.
Historically, ALS has affected approximately 9 in 100,000 people in the United States. As scientific understanding of the risk factors associated with ALS continues to evolve, the need for more nuanced research into the connections between psychiatric illness and neurodegenerative diseases becomes increasingly critical. This study serves as a reminder of the complex relationship between mental health treatments and neurological outcomes, calling for further investigation into the long-term effects of psychiatric medications.
As researchers continue to explore these associations, there is hope that a deeper understanding of the underlying mechanisms may one day lead to effective treatments for ALS and improve the lives of those affected by both psychiatric and neurodegenerative conditions.
Advertisement
Tags
Advertisement